Search | Clinical Trials Finder

Conditions: Clostridium Difficile
Interventions: C. difficile vaccine with adjuvant, placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 184 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: Overland Park, Kansas • Cary, North Carolina • Raleigh, North Carolina + 2 more

Conditions: Breakthrough Bleeding
Interventions: DR-1031, Seasonale®, Portia®; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 567 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 50
States / cities: Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 45 more

Conditions: Mild Cognitive Impairment Due to Alzheimer's Disease
Interventions: Pioglitazone, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 65 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 28
States / cities: Phoenix, Arizona • Sun City, Arizona • San Diego, California + 25 more

Conditions: Opioid Use, Opioid Dependence, Opioid-use Disorder, Narcotic Use, Back Pain, Back Injuries, Chronic Pain, Chronic Low-back Pain, Pain, Chronic, Pain;Back Low;Chronic, Pain, Back
Interventions: Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet, Naproxen 500 Mg, Opioids; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Labor Pain
Interventions: Multiport flexible catheter, Uniport flexible catheter; Device
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Bowel Preparation
Interventions: Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution, Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 917 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 12
States / cities: Huntsville, Alabama • Anaheim, California • Chula Vista, California + 9 more

Conditions: Healthy
Interventions: sotrastaurin, placebo to sotrastaurin, Avelox; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Electrocardiogram Repolarisation Abnormality, Gonococcal Infection
Interventions: AZD0914, Moxifloxacin, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Cerebral Edema, Brain Metastases
Interventions: Glyburide, Placebo; Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Fertility Preservation
Interventions: OCP pause; Other
Lead sponsor: Shady Grove Fertility Reproductive Science Center; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Orange, Connecticut • Rockville, Maryland • New York, New York

Conditions: Chronic Low Back Pain
Interventions: Naproxen, Placebo, Omeprazole; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy
Interventions: TD-1473 for SAD, Placebo for SAD, TD-1473 for MAD, Placebo for MAD; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Depressive Disorder
Interventions: Star*D algorithm, rEEG-guided therapy; Other
Lead sponsor: MYnd Analytics; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 13
States / cities: Glendale, California • Irvine, California • San Bernardino, California + 10 more

Conditions: Psychosis, Schizophrenia Disorder, Schizoaffective Disorder, Major Depressive Disorder With Psychotic Features, Bipolar Disorder With Psychotic Features, Psychosis NOS, Schizophreniform Disorder, Psychotic Disorder, Cognition
Interventions: Modafinil, D-serine solution, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 35 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Status Asthmaticus
Interventions: Ipratropium, 0.9% Sodium Chloride, Albuterol, corticosteroids; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 2 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Osteoporosis, Postmenopausal Osteoporosis
Interventions: Placebo, BA058 80 mcg, teriparatide; Drug
Lead sponsor: Radius Health, Inc.; Industry
Eligibility: 50 Years to 85 Years · Female only
Enrollment: 2,463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 5
States / cities: Lakewood, Colorado • Miami, Florida • North Miami, Florida + 2 more

Conditions: Cardiovascular Outcomes
Interventions: Niaspan, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Refractory Migraine
Interventions: Botox, Placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: NNC0194-0499, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 22 Years to 55 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Amyotrophic Lateral Sclerosis
Interventions: CK0803, Excipient; Biological · Other
Lead sponsor: Cellenkos, Inc.; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: New York, New York • Houston, Texas

Conditions: Healthy Participants
Interventions: BMS-986308, Placebo (for BMS-986308), Furosemide; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Osteoarthritis, Rheumatoid Arthritis, Avascular Necrosis
Interventions: Placebo, Lacosamide; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Healthy Volunteers
Interventions: IP, Matching Placebo; Drug
Lead sponsor: Nurix Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Search by objective public record fields.

A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.

A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale

AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease

Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure

Analgesic Efficacy of a Multiport Versus Uniport Flexible Catheter for Labor Epidural Analgesia

A Study Comparing the Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution With PREPOPIK® for Colon Cleansing in Preparation for Colonoscopy

CAEB071 Thorough QTc Study in Healthy Volunteers

Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects

Glyburide vs Placebo as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases (RAD 1502/UAB 1593)

Hormonal Optimization: Late vs. Immediate Start After Discontinuation of Oral Contraceptives in Assisted Reproductive technologY (HOLIDAY)

Placebo In Chronic Back Pain - Double-Blind Randomized Control Trial

SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects

rEEG Guided Pharmacotherapy of Subjects With Depression Treatment Failure

Cognitive Strategies in Early Psychosis 2

Phase I, Placebo-Controlled, Blinded Pilot Study of Ipratropium in Children Admitted to the ICU With Status Asthmaticus

Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women

Benefit of Elevation of HDL-C in Women

Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches

A Longitudinal Study of Brain Atrophy in MS Patients Over 5 Years

A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity

Regulatory T Cells for Amyotrophic Lateral Sclerosis

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants

Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty:

A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects